Brent L Saunders sold $1.7M of SPRY
director at ARS Pharmaceuticals, Inc.. 120,000 shares at an average of $14.25, traded May 20, 2025, filed May 22, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.7M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-014185, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 20, 2025 | MOption exercise Common Stock | +120,000 | $1.01 | $121k | 120,000 | May 22, 2025 |
| May 20, 2025 | SOpen-market sale Common Stock | -120,000 | $14.25 | $1.7M | 0 | May 22, 2025 |
| May 20, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -120,000 | $0.00 | $0 | 470,950 | May 22, 2025 |
Related signals
Other insiders at ARS Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ARS Pharmaceuticals, Inc. | Brian Dorsey Chief Operating Officer | $190k 21,828 shares | -67% | |
| 53Moderate | ARS Pharmaceuticals, Inc. | Justin Chakma Chief Business Officer | $1.5M 166,380 shares | -100% | |
| 34Weak | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $188k 12,500 shares | -55% | |
| 41Moderate | ARS Pharmaceuticals, Inc. | Richard E Lowenthal PRESIDENT AND CEO | $724k 50,000 shares | -4% | |
| 31Weak | ARS Pharmaceuticals, Inc. | Sarina Tanimoto CHIEF MEDICAL OFFICER | $704k 50,000 shares | -4% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $255k 15,000 shares | -59% | |
| 50Moderate | ARS Pharmaceuticals, Inc. | James E Flynn owner | $14M 740,149 shares | -14% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $240k 15,000 shares | -66% | |
| 63Notable | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $705k 50,000 shares | -87% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Alexander A Fitzpatrick Chief Legal Officer | $1.5M 102,969 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.